Royce & Associates LP boosted its holdings in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 23.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 484,286 shares of the company's stock after buying an additional 91,000 shares during the period. Royce & Associates LP owned approximately 0.90% of CareDx worth $10,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CDNA. Quarry LP acquired a new position in shares of CareDx during the third quarter valued at about $27,000. Thompson Davis & CO. Inc. grew its position in CareDx by 6.3% during the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock worth $344,000 after purchasing an additional 950 shares during the last quarter. Principal Financial Group Inc. increased its stake in CareDx by 6.5% during the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after purchasing an additional 1,151 shares in the last quarter. Plato Investment Management Ltd raised its holdings in shares of CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock worth $116,000 after buying an additional 1,370 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of CareDx by 1.8% during the fourth quarter. Rhumbline Advisers now owns 81,201 shares of the company's stock worth $1,738,000 after buying an additional 1,451 shares during the period.
CareDx Price Performance
CDNA stock traded up $0.42 during trading on Friday, hitting $19.32. 778,253 shares of the company traded hands, compared to its average volume of 834,012. CareDx, Inc has a 1 year low of $7.42 and a 1 year high of $34.84. The company has a market cap of $1.07 billion, a PE ratio of -7.16 and a beta of 1.95. The stock's 50-day simple moving average is $21.88 and its 200 day simple moving average is $24.07.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. Research analysts expect that CareDx, Inc will post -0.9 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on CDNA. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Stephens restated an "overweight" rating and issued a $40.00 price objective on shares of CareDx in a research note on Thursday, February 27th. HC Wainwright dropped their target price on CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and cut their price target for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $31.83.
Get Our Latest Stock Report on CareDx
CareDx Company Profile
(
Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Articles
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
